Literature DB >> 24021580

Non-radiographic axial spondyloarthritis: what is it?

E Fianyo1, D Wendling, C Poulain, V Farrenq, P Claudepierre.   

Abstract

The classification criteria recently developed by the Assessment of Spondyloarthritis International Society (ASAS) highlighted a specific entity: non radiographic axial spondyloarthritis (nr-axSpA). Although more and more widely used in the literature as well as clinical trials, limits and profile of this entity is still under known or debated. Some studies have already compared those forms to classical AS, even in recent forms. They showed that, apart from the difference in the ossification process, and the greater degree and frequency of systemic and MRI inflammation in AS, those 2 forms of SpA share the same genetic background, clinical patterns, and burden of disease. TNF antagonists seemed as effective in controlling symptoms in patients with nr-axSpA. Concerning the long-term outcome of nr-ax-SpA, only long-term ongoing cohorts of patients with recent nr-axSpA will be able to determine what proportion of patients have persistent non-radiographic disease and what proportion do progress to AS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24021580

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  2 in total

1.  The journey of the non-radiographic axial spondyloarthritis patient: the perspective of professionals and patients.

Authors:  Teresa Otón; Carlos Sastre; Loreto Carmona
Journal:  Clin Rheumatol       Date:  2020-07-06       Impact factor: 2.980

2.  Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.

Authors:  Luca Cantarini; Marta Fabbroni; Rosaria Talarico; Luisa Costa; Francesco Caso; Gian Luca Cuneo; Bruno Frediani; Gabriele Faralli; Antonio Vitale; Maria Giuseppina Brizi; Luciano Sabadini; Mauro Galeazzi
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.